TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Effectiveness of Anti-Gravity Treadmill Training

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults between 18 and 65 years old~* Willing and able to comply with protocol and PT requirements~* Patients with primarily radicular and back pain due to degenerative disc disease requiring one-level discectomy for herniated disc or lumbar fusion between L2 and S1~* Willing and able to sign a study specific informed consent~Exclusion Criteria:~* Require more than one-level surgery~* No previous lumbar surgery~* Any ongoing health condition that would make it difficult to adhere to postoperative PT requirements~* Peri-operative or post-operative complications (infection, pneumonia, nerve injury, dural tear, etc.) that would constraint or delay the ability to participate in postoperative PT~* BMI greater than 40~* Active local or systemic infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AlterG and Physical therapy (Type: None): 2) Standard postoperative rehabilitation program with addition of lower body positive pressure (LBPP) treadmill training
- Control group (Type: None): 1) Standard postoperative rehabilitation program

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Patient-Derived Xenograft (PDX) Modeling in Adult Patients With Metastatic or Recurrent Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
* 15 years of age or older~* Patients with metastatic sarcoma who have had no more than one prior systemic treatment for metastatic disease~* Patients with recurrent sarcoma at relapse~* Patients with confirmed histological diagnosis of sarcoma or suspected diagnosis of sarcoma. Some specific subtypes of sarcoma are NOT eligible (Gastrointestinal Stromal Tumor (GIST), carcinosarcoma, sarcomatoid mesothelioma, and metastatic phyllodes tumor)~* If initial suspected diagnosis of sarcoma, must have sarcoma diagnosis confirmed prior to proceeding with PDX drug sensitivity testing~* Must have measureable disease for computed tomography (CT) scan or magnetic resonance imaging (MRI) evaluation following biopsy or surgery to obtain tissue for PDX development.~* No plan for concurrent chemoradiation, for target lesions that will be used for drug treatment correlation with PDX~* Fresh tumor tissue available for PDX development~* Eastern Cooperative Oncology Group performance status of 0-1~* Life expectancy exceeds 6 months~* Plan to receive systemic therapy~* Informed consent

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PDX drug sensitivity testing (Type: OTHER): Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Survey of QRS Frequency at Various Left Ventricular Pacing Sites for Cardiac Resynchronization

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Standard implantation for cardiac resynchronization ICD or PM implantation~* Cardiomyopathy with LVEF \<35%~* QRS duration greater than 120 msec~Exclusion Criteria:~- Age less than 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Coronary Sinus Branch Pacing (Type: EXPERIMENTAL): After cannulation, pacing impulses will be delivered via a Biotronik Vision Guidewire to 3 sites (apical, mid ventricular, and basal) within each coronary sinus branch receiving venous blood from the anterior, lateral and posterior regions of the ventricle.~ECG signals will be saved digitally for analysis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: I2PETPG - Imidazoline2 Binding Sites in a Group of Participants Diagnosed With AD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male aged 50 to 80 years~* Subjects who meet the NIA-AA core clinical criteria for probable Alzheimer's disease dementia~* Clinical Dementia Rating (CDR) score of 0.5 or more and MMSE ≥ 17~* Subjects on acetylcholinesterase inhibitor or memantine therapy for Alzheimer's disease must be on a stable dose prior to baseline~* Subjects must have partners/caregivers able to accompany them during the study visits, as well as monitor for, and report, any adverse events to the study team in the week after scanning~* Non-smoker~* Willing to comply with protocol and lifestyle restrictions~* Excellent understanding of English (for questionnaires)~* Participant is ambulant and capable of attending a PET scan visit as an outpatient.~* Participants with female partners of child-bearing potential must agree to use one of the contraception methods listed in Section 7.5.1. This criterion must be followed from after the first PET Scan until after the follow-up contact.~* Adequate collateral flow to the radial and ulnar arteries in both hands as determined by an Allen's test.~* Body weight ≥50 kg.~Exclusion Criteria:~* Current or past history of major psychiatric disorder~* Current or past history of substance use disorder~* Clinically significant brain injury or abnormality~* Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).~* History of or suffers from claustrophobia or subject feels unable to lie flat and still on their back for a period of up to 2 hours in the PET/CT scanner.~* Previous inclusion in a research and/or medical protocol involving nuclear medicine, PET or radiological investigations or occupational exposure resulting in radiation exposure greater than 10 mSv over the past 3 years or greater than 10 mSv in a single year including the proposed study. Clinical exposure from which the subject receives a direct benefit is not included in these calculations.~* Previous inclusion in a research and/or medical protocol involving study medication within the last 3 months~* In the opinion of the study team they are unlikely to comply with the study protocol and restrictions that it imposes.~* Contraindications for subjects undergoing an MR scan (including but not limited to metal implants pacemakers, etc.)

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Patient Group (Type: EXPERIMENTAL): Baseline PET scan followed by a blocked PET scan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Validation of the MiCK Assay

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 20 subjects diagnosed with mesothelioma and 10 diagnosed with any malignancy.~Exclusion Criteria:~* patients that a sample cannot obtained for testing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mesothelioma (Type: None): None
- all cancer types (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Rhinogenic Headache Improvement After Nasal Operation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic (\> 2 months) pain or pressure over nasal bridge, glabella, or forehead~* Unilateral or bilateral nasal septal deviation that is chronically symptomatic (e.g. nasal airway obstruction)~* Failure of standard medical therapy for headache~* Symptomatic contact points as demonstrated by physical examination, sinus CT and nasal endoscopy~* Relief of headache after application of topical anesthetic to contact points~* Contact points that remain after mucosal decongestion~* Absence of any other obvious cause of headaches after a thorough evaluation by a neurologist, ophthalmologist, dentist, internist, or other related specialist~Exclusion Criteria:~* Previous sinonasal surgery~* Active acute sinonasal disease:~  1. Seasonal allergic exacerbations with mucosal swelling~ 2. Acute infectious rhino-sinusitis~* Chronic sinonasal problems:~  1. Severe nasal polyps mimicking contact points~ 2. Mucoceles protruding from sinuses into nasal cavity~ 3. Nasal and sinus tumors~* General medical condition that precludes elective surgery (including pregnancy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Septoplasty (Type: PLACEBO_COMPARATOR): Septoplasty only
- Septoplasty and correction (Type: EXPERIMENTAL): Septoplasty and endoscopic contact point correction

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oocyte Cryopreservation Study (Egg Banking)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age between 15 and 45~* desire oocyte cryopreservation or use of cryopreserved oocytes for the purposes of achieving pregnancy~* willingness to participate in study and provide informed consent~Exclusion Criteria:~* day 3 FSH over 20 mIU/ml, or Day 3 E2 over 100pg/ml~* ovarian cyst greater than 14mm at baseline ultrasound~* uncontrolled medical illness such as diabetes, hypertension, or cardiovascular disease~* current pregnancy

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Chiropractic Care and a Specific Regimen of Nutritional Supplementation for Patients With Acute Ankle Sprain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute ankle sprain, defined as ankle sprain within the past 7 days, by patient report. Treating clinician will verify diagnosis via clinical examination.~* Ages 18-50; ankle sprains are more common in this age group.~Exclusion Criteria:~* Diagnosis of grade III ankle sprain, fracture or dislocation; fracture will be diagnosed using the Ottawa ankle rules11,12~* Contraindications to chiropractic care, such as fracture or other abnormalities found by history, examination, or x-rays, as determined by the treating or supervising clinician.~* Pregnancy: although it is unlikely that the nutritional supplements would have adverse effects on the fetus, we are excluding pregnant women as a safeguard.~* Unwilling or unable to regularly take the supplements (e.g., vegetarians; known sensitivity by self-report; patients will be shown the ingredient list prior to signing the informed consent).~* Litigation for a health-related claim (in process or pending).~* History of ankle surgery or presence of ankle hardware (pins, screws, etc.), by patient report.~* History of diabetic or other peripheral neuropathy, by patient report.~* Current use of prescription or nonprescription medications that may interact with experimental or placebo supplements, by patient report.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Acute phase (1st treatment through Week 4): Placebo. 2 capsules 3 x day. Chronic phase (Weeks 5-16): Placebo. 1 capsule 3 x day.
- dietary supplement (Type: EXPERIMENTAL): Acute phase (1st treatment through Week 4): Ligaplex 1. Ligaplex 1 supplies nutrients to support connective tissue and reduce inflammation. The protocol is commonly used in chiropractic practice and suggested by Standard Process: 2 capsules 3 x day.~Chronic phase (Weeks 5-16): Glucosamine Synergy. This supplement maintains connective tissue and joint health. The protocol is commonly used in chiropractic practice and suggested by Standard Process: 1 capsule 3 x day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Methadone Demonstration Project With Neonatal Intensive Care Unit Infants Diagnosed With Neonatal Abstinence Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Methadone Treatment Group:~Inclusion criteria:~1. Baby is diagnosed with neonatal abstinence syndrome;~2. Mother under the care of Operation PAR;~3. Mother resides in Pinellas or Pasco county at the time of enrollment and is expected to throughout the infant's methadone treatment period;~4. Mother has been deemed by PAR officials as being compliant with the detoxification program;~5. Mother has completed induction methadone treatment and has had no changes in medication dosage of 10% or greater in the two weeks preceding delivery;~6. Mother has been prescreened and deemed adequate candidate by the demonstration project team members;~7. No known concerns from Florida Department of Children and Families regarding the infant's ability to return to the home;~8. Newborns ≥ 37 0/7 weeks gestation;~9. Newborns transferred to JHACH within 72 hours from birth;~10. Newborns ≥ 2.5 kg weight at birth;~11. Informed parental consent.~Exclusion Criteria:~1. Major congenital anomalies;~2. Major concomitant medical illness including planned antibiotic treatment for greater than 3 days or NPO status;~3. Infants who are being placed for adoption;~4. Infants in significant pain requiring narcotic medication for comfort (for example those with a fracture);~5. Infants whose maternal UDS at the time of delivery is positive for any other drug of abuse beside opiates.~6. Mother with hearing or language impairment~Comparison Group:~Inclusion Criteria:~1. Baby is diagnosed with neonatal abstinence syndrome;~2. Newborns ≥ 37 0/7 weeks gestation;~3. Newborns transferred to JHACH within 72 hours from birth;~4. Newborns ≥ 2.5 kg weight at birth;~5. Informed parental consent.~Exclusion Criteria:~1. Infant not requiring pharmacologic treatment for NAS;~2. Major congenital anomalies;~3. Major concomitant medical illness including planned antibiotic treatment for greater than 3 days or NPO status;~4. Infants who are being placed for adoption;~5. Infants in significant pain requiring narcotic medication for comfort (for example those with a fracture);~6. Mother with hearing or language impairment;~7. Infants known upon admission who will be placed into state custody or sheltered.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 72 Hours
- Healthy Volunteers: f

Study Arms:
- Methadone Treatment Group (Type: EXPERIMENTAL): NAS infants treated for withdrawal symptoms with methadone
- Comparison Group (Type: ACTIVE_COMPARATOR): NAS infants treated for withdrawal symptoms with morphine (standard of care at Johns Hopkins All Children's Hospital)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of a Remediation Program of Social Cognition in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Schizophrenia following DSM IV;~* Age 18-57;~* Stability of the clinical state;~* Ability to learn;~* Deficit in intention reading as measure with the V-SIR (V-LIS in French) test (score \>13);~* informed consent to participate to the study.~Exclusion Criteria:~* Any other organic or neuropsychiatric disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 57 Years
- Healthy Volunteers: f

Study Arms:
- original cognitive therapy (Type: EXPERIMENTAL): None
- no intervention (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* IPAH~* \> 3 months treatment with bosentan~* 6 minute walk distance 150 - 425 m~Exclusion Criteria:~* other forms of pulmonary hypertension~* severe comorbidities~* cotreatment with sildenafil or investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Aerosolized Iloprost (Type: ACTIVE_COMPARATOR): None
- Bosentan monotherapy (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Elitek (Rasburicase) Immuno-Monitoring Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~1. Previous history of rasburicase exposure and history of administration of a repeat (2nd) series of rasburicase injections (in the context of supportive care for relapsing leukemia/lymphoma) and subsequent development of either a hypersensitivity reaction (HSR) or loss of uricolytic activity (defined as failure to achieve uric acid level of \< or = 7.5 mg/dl measured 48 hours after the first rasburicase injection).~   1. A severe hypersensitivity reaction (NCI Grade 3, 4 or 5) is defined as:~      Allergic reaction; allergy; anaphylactic shock; bronchospasm; bullous skin eruption; dermatitis - exfoliative; drug hypersensitivity; dyspnea; hypotension; hypoxia; rash; rash - erythematous; rash - maculopapular, urticaria; pyrexia/fever; edema; chest discomfort; hypersensitivity (NOS); pharynx discomfort; hoarseness; pharyngeal erythema; pruritus; erythema; localized exfoliation; rash - papular; swelling ¿ face/facial; toxic skin eruption; hot flush; flushing; rash - macular; rash - pruritic; pruritus - allergic.~  2. Loss of uricolytic activity can be defined as:~      * uric acid levels \> 7.5 mg/dl measured 48 hours after the first rasburicase injection¿, which is a time point coincident with administration of the third dose of rasburicase (within that second course of treatment with this agent).~2. Patients should have received at least 2 doses of rasburicase during the repeat (2nd) administration in the event of loss or uricolytic activity. At least 1 dose of rasburicase should be administered during the repeat (2nd) administration for diagnosis of HSR.~Exclusion criteria:~1. Concomitant treatment with human IV immunoglobulin (IVIG)~2. Concomitant treatment with TNF-alpha antagonists/inhibitors, i.e. adalimumab, infliximab, and etanercept~3. Concomitant treatment with Interferon-alpha (IFN-alpha)~4. Unwillingness or inability to comply with the requirements of the protocol.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anti-rasburicase antibodies (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues